CD44 and ovarian carcinoma: Following the interaction of CD44 with HA, ankyrin binds to multidrug resistance mutation 1 (MDR1) leading to doxorubicin efflux and paclitaxel and chemoresistance in both breast and ovarian cancer cells (70).